These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 11316672)

  • 1. Lung deposition of inhaled drugs increases with age?
    Amirav I; Newhouse MT
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1279. PubMed ID: 11316672
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children.
    Agertoft L; Pedersen S
    Am J Respir Crit Care Med; 2003 Oct; 168(7):779-82. PubMed ID: 12893646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung deposition of inhaled drugs increases with age.
    Onhøj J; Thorsson L; Bisgaard H
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1819-22. PubMed ID: 11069819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic availability of Rhinocort Aqua (budesonide) nasal spray: importance of formulation and definition of delivered dose.
    O'Dowd L; Thorsson L; Edsbacker S
    J Allergy Clin Immunol; 2002 Jun; 109(6):1037; author reply 1037-8. PubMed ID: 12063539
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacological and clinical profile of Budesonide inhalation suspension (Pulmicort inhalation liquid), an inhaled steroid drug for asthma].
    Watanabe H; Yano S; Kageyama A
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):197-207. PubMed ID: 17379972
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of the pulmonary deposition and in vitro permeability on the prediction of plasma levels of inhaled budesonide formulation.
    Salar-Behzadi S; Wu S; Mercuri A; Meindl C; Stranzinger S; Fröhlich E
    Int J Pharm; 2017 Oct; 532(1):337-344. PubMed ID: 28890175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide and risk of pneumonia.
    Black PN; Sexton PM
    Lancet; 2009 Dec; 374(9707):2050-2051. PubMed ID: 20109825
    [No Abstract]   [Full Text] [Related]  

  • 8. A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children.
    Schüepp KG; Devadson S; Roller C; Wildhaber JH
    Swiss Med Wkly; 2004 Apr; 134(13-14):198-200. PubMed ID: 15106033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalation of aerosols by children: an ongoing controversy.
    Schöni MH
    Swiss Med Wkly; 2004 Apr; 134(13-14):173-4. PubMed ID: 15106030
    [No Abstract]   [Full Text] [Related]  

  • 10. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U; Marschall K; Fyrnys B; Wedel M
    Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic availability and lung deposition of budesonide via three different nebulizers in adults.
    Dahlström K; Thorsson L; Larsson P; Nikander K
    Ann Allergy Asthma Immunol; 2003 Feb; 90(2):226-32. PubMed ID: 12602671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrimination of prohibited oral use from authorized inhaled treatment of budesonide in sports.
    Matabosch X; Pozo OJ; Pérez-Mañá C; Farré M; Marcos J; Segura J; Ventura R
    Ther Drug Monit; 2013 Feb; 35(1):118-28. PubMed ID: 23318282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats.
    Jones RM; Harrison A
    Xenobiotica; 2012 Jan; 42(1):75-85. PubMed ID: 22077102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing inhaled corticosteroid therapy in children with chronic asthma.
    O'Connell EJ
    Pediatr Pulmonol; 2005 Jan; 39(1):74-83. PubMed ID: 15532098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
    Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide.
    Thorsson L; Geller D
    Respir Med; 2005 Jul; 99(7):836-49. PubMed ID: 15939245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma.
    Kemp J; Wanderer AA; Ramsdell J; Southern DL; Weiss S; Aaronson D; Grossman J
    Ann Allergy Asthma Immunol; 1999 May; 82(5):463-71. PubMed ID: 10353578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide.
    Nikander K; Agertoft L; Pedersen S
    J Asthma; 2000 Aug; 37(5):451-9. PubMed ID: 10983623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.
    Lähelmä S; Kirjavainen M; Kela M; Herttuainen J; Vahteristo M; Silvasti M; Ranki-Pesonen M
    Br J Clin Pharmacol; 2005 Feb; 59(2):167-73. PubMed ID: 15676038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma.
    Shrewsbury SB; Bosco AP; Uster PS
    Int J Pharm; 2009 Jan; 365(1-2):12-7. PubMed ID: 18786624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.